Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

Chugai Launches Tecentriq Intravenous Infusion 840 mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

Shots:

  • Tecentriq (atezolizumab, q2w) Intravenous Infusion 840mg has been listed on the NIH reimbursement price list and launched by Chugai as an optimal formulation to treat PD-L1-positive hormone receptor-negative and HER2-negative inoperable or recurrent BC
  • The P-III IMpassion130 study involve assessing of Tecentriq + nab-paclitaxel (albumin-bound) vs nab-paclitaxel (albumin-bound) in patients with unresectable LA/metastatic TNBC prior not treated with systemic therapy for mBC
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1receptors and has received MHLW’s approval for this indication and dosage form on Sep 20, 2019

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical | Image: Business Insider